Interní Med. 2005; 7(10): 454-456

ASCOT - Anglo-Scandinavian Cardiac Outcomes Trial

prof. MUDr. Jindřich ©pinar CSc., FESC, prof. MUDr. Jiří Vítovec CSc., FESC
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Studie ASCOT – Anglo-Scandinavian Cardiac Outcomes Trial – porovnávala léčbu hypertoniků s více rizikovými faktory na kombinaci amlodipin/perindopril proti kombinaci atenolol/bendroflumethiazid. Studie byla předčasně ukončena pro statisticky významně niľąí mortalitu, výskyt koronárních příhod a výskyt cévní mozkové příhody u nemocných léčených kalciovým blokátorem, případně ACE inhibitorem.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J. ASCOT - Anglo-Scandinavian Cardiac Outcomes Trial. Interní Med. 2005;7(10):454-456.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Altman LK. Use of some hypertension drugs questioned. The New York Times 29. 8. 2000; sekce A, odstavec 1, s. 17.
    2. Cífková R, Horký K, Widimský J sr, Widimský J jr, Filipovský J, Grundmann M, Monhart V, Rosolová H, Souček M, ©pinar J, Vítovec J. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2004; 50 (9): 709-722. Go to PubMed...
    3. Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    4. Dahlof B. for the ASCOT investigators: Prevention of coronary stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-1158. Go to original source... Go to PubMed...
    5. Chobanian AV, Bakris GL, Black HR. National heart, lung and blood institute joint national committee on prevention, detection, evaluation and treatment of high blood pressure - Seventh report. JAMA 2003; 291: 2560-2572. Go to original source... Go to PubMed...
    6. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. Go to original source... Go to PubMed...
    7. Messerli FH, Sichrovsky T. When premature is not premature - the ASCOT study. European Heart Journal 2005; 26: 1822-1823. Go to original source... Go to PubMed...
    8. Nissen SE, Tuzcu EM Libby P, for the CAMELOT investigators: CAMELOT (Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure). JAMA 2004; 292: 2217-2226. Go to original source... Go to PubMed...
    9. Pepine CJ. for the INVEST investigators: INVEST: International Verapamil SR/ Trandolapril Study. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
    10. Poulter NR fot the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    11. Poulter NR. Announcement about ASCOT-LLA. Lancet 2004; 363: 1478. Go to original source...
    12. The ALLHAT Officers ond Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. Go to original source... Go to PubMed...
    13. Vítovec J, ©pinar J. Farmakoterapie kardiovaskulárních onemocnění. Praha: Grada, 2004: 248.
    14. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363: 2047-2049. Go to original source... Go to PubMed...
    15. Widimský J. a kol. Hypertenze 2. vydání. Triton Praha 2004; 590 s.
    16. Widimský J. jr. Studie ASCOT. Cor et Vasa 2005; 47 (10): v tisku.
    17. Zanchetti A. for the Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1053. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.